Human papillomavirus antigen peptide–major histocompatibility complex (HPV antigen peptide–MHC)

HPV antigen peptides presented by the major histocompatibility complex (MHC) refer to short peptide fragments derived from HPV proteins (most often the E6 and E7 oncoproteins) that are processed inside infected or malignant cells and then displayed on the cell surface by MHC molecules, either class I (presenting to CD8+ cytotoxic T cells) or class II (presenting to CD4+ helper T cells). This peptide–MHC complex acts as a specific ligand for T cell receptors (TCRs), enabling antigen-specific immune recognition and cell-mediated immune clearance. In the context of cancer immunotherapy, these complexes are critical therapeutic targets for vaccines and adoptive T cell therapies aiming to direct the immune system against HPV-driven tumors, and are important biomarkers for monitoring immune responses or predicting therapeutic response. Limitations include immune evasion by tumor downregulation of antigen presentation machinery or MHC, and the requirement for strict peptide–MHC specificity to avoid autoimmunity or therapeutic failure.

Other names

HPV-derived antigen peptide–MHC complexHPV peptide–major histocompatibility complexHPV peptide–HLA complex (for human context, as HLA is the human MHC)HPV antigenic epitope (MHC-presented)HPV pMHC (peptide-loaded MHC complex)

Antigenic HPV peptides complexed with MHC are recognized by T-cell receptors (TCRs) on HPV-specific CD8+ cytotoxic and CD4+ helper T cells, leading to targeted immune responses against infected or malignant cells expressing the HPV antigen. Therapeutic vaccines induce or amplify T cell populations recognizing specific HPV peptide–MHC complexes. Checkpoint inhibitors facilitate T cell activation after TCR engagement with HPV peptide–MHC.